Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
Charlotte C van RuitenDick J VeltmanAnouk SchranteeLiselotte van BloemendaalFrederik BarkhofMark H H KramerMax NieuwdorpRichard G IJzermanPublished in: The Journal of clinical endocrinology and metabolism (2022)
The early increase in CNS activation with dapagliflozin may contribute to the discrepancy between observed and expected weight loss. In combination therapy, exenatide blunted the increased CNS activation observed with dapagliflozin. These findings provide further insights into the weight-lowering mechanisms of SGLT2i and GLP-1 receptor agonists.